Journal of Chemotherapy最新文献_第10页

Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals. 西班牙医院使用奥拉帕尼治疗胰腺癌的真实证据

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-03-09 DOI: 10.1080/1120009X.2026.2639277

Héctor Carlos García-Díaz, Javier Gómez-Alonso, María Teresa Rabuñal-Álvarez, María Ochagavía, José Luis Revuelta-Herrero, Álvaro González-Gómez, Ana C Riestra, Aina Oliver-Noguera, María Moreno García, Anna Farriols, Teresa Macarulla, Maria J Carreras, María Larrosa-Garcia

{"title":"Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals.","authors":"Héctor Carlos García-Díaz, Javier Gómez-Alonso, María Teresa Rabuñal-Álvarez, María Ochagavía, José Luis Revuelta-Herrero, Álvaro González-Gómez, Ana C Riestra, Aina Oliver-Noguera, María Moreno García, Anna Farriols, Teresa Macarulla, Maria J Carreras, María Larrosa-Garcia","doi":"10.1080/1120009X.2026.2639277","DOIUrl":"10.1080/1120009X.2026.2639277","url":null,"abstract":"Patients with pancreatic cancer (PC) harboring DNA damage repair genes (DDRg) alterations, particularly BRCA1/2, may benefit from olaparib. Although the phase III POLO trial demonstrated improved progression-free survival (PFS) with olaparib as maintenance therapy in germline BRCA-mutated metastatic PC, real-world data, especially in patients with non-BRCA DDR alterations, remain limited. The objective of this study is to evaluate the real-world effectiveness and safety of olaparib in PC patients harboring DDRg alterations. A multicenter, retrospective observational study was conducted across eight Spanish hospitals. Adult patients with PC and DDRg alterations who initiated olaparib between December 2018 and October 2022 were included. Data were extracted from electronic medical records. PFS and overall survival (OS) were estimated using the Kaplan-Meier method. Adverse events (AEs) were assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. A total of 24 patients were included, most commonly harboring gBRCA2 (58.3%), sBRCA2 (16.7%) or ATM (16.7%) alterations. Among patients receiving olaparib as maintenance therapy (87.5%), the objective response rate (ORR) was 33.3%, the median PFS was 10.4 months (95% CI, 1.7-19.1) and the median OS was 32.9 months (95% CI, 20.1-45.6). At data cutoff, the OS rate >20 months was 71.4% and >30 months was 42.9%. Grade ≥3 AEs occurred in 16.7% of patients. This multicenter real-world study olaparib showed clinical activity and acceptable safety profile in PC patients harboring DDRg mutations, including those beyond BRCA. Further studies are needed to validate these findings and to better identify patients who may benefit from olaparib, particularly those with non-BRCA mutations.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147390133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis. alk阳性非小细胞肺癌脑转移患者全身治疗的颅内疗效：系统回顾和荟萃分析

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-02-23 DOI: 10.1080/1120009X.2026.2635794

Diego A Hernandez, Gabriela Petersen, Jimena Gonzalez-Salido, Jorge Lopez, Diego A Diaz Garcia

{"title":"Intracranial efficacy of systemic therapies for patients with ALK-positive non-small cell lung cancer in patients with brain metastases: a systematic review and meta-analysis.","authors":"Diego A Hernandez, Gabriela Petersen, Jimena Gonzalez-Salido, Jorge Lopez, Diego A Diaz Garcia","doi":"10.1080/1120009X.2026.2635794","DOIUrl":"10.1080/1120009X.2026.2635794","url":null,"abstract":"Lung cancer remains the leading cause of cancer-related mortality worldwide. Among patients with advanced non-small cell lung cancer (NSCLC), ALK-positive disease accounts for roughly 5% of cases We conducted a systematic search of PubMed, Embase, Cochrane, Web of Science, and ClinicalTrials.gov for randomized controlled trials comparing first-line ALK inhibitors with crizotinib or platinum-based chemotherapy and reporting intracranial outcomes. Eight trials (2,250 patients) met inclusion criteria. Median age ranged from 49 to 61 years, and baseline CNS metastases were present in 25.9% to 42% of participants. Second- and third -generation ALK TKIs showed a trend toward improved intracranial objective response rate (icORR) among patients with baseline brain metastases(RR 1.92, 95% CI: 0.58-6.44; p = 0.21). Lorlatinib, a third-generation ALK inhibitor, demonstrated a superior icORR in patients with measurable intracranial disease (RR 3.57, 95% CI: 1.29-9.86) and also showed higher intracranial complete response rates (RR 4.04, 95% CI 1.85-8.81). The safety profile was comparable between second- and third-generation ALK TKIs, with alectinib reporting fewer grade ≥3 adverse events (RR 0.72, 95% CI 0.58-0.88). These findings support the use of second- and third-generation ALK TKIs, particularly lorlatinib, as preferred first-line options for patients presenting with brain metastases at diagnosis.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147271189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cisplatin-based chemotherapy is a possible risk factor for cerebral stroke in patients with testicular germ cell tumour - a case report and review of the literature. 以顺铂为基础的化疗是睾丸生殖细胞肿瘤患者脑卒中的一个可能的危险因素——一个病例报告和文献综述。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-02-16 DOI: 10.1080/1120009X.2026.2631299

Klaus-Peter Dieckmann, Markus Angerer, Bernd Eckert, Anna Alegiani, Christian Wülfing

{"title":"Cisplatin-based chemotherapy is a possible risk factor for cerebral stroke in patients with testicular germ cell tumour - a case report and review of the literature.","authors":"Klaus-Peter Dieckmann, Markus Angerer, Bernd Eckert, Anna Alegiani, Christian Wülfing","doi":"10.1080/1120009X.2026.2631299","DOIUrl":"10.1080/1120009X.2026.2631299","url":null,"abstract":"Cerebral stroke secondary to cisplatin-based chemotherapy in young patients undergoing chemotherapy for testicular germ cell tumour (GCT) has been reported only sporadically. Here, we report a 49-year-old man undergoing adjuvant chemotherapy with one cycle of bleomycin, etoposide, and cisplatin for nonseminomatous testicular GCT clinical stage 1b. On the sixth day of treatment, a sudden onset of right-sided hemiparesis and aphasia prompted computed tomography and angiography. An occlusion of the left middle cerebral artery was detected. The patient recovered after immediate thrombolytic therapy, but minor neurological deficits were present 9 months after the event. Among 221 GCT patients undergoing cisplatin-based chemotherapy during 2017-2025, one stroke occurred, revealing a relative incidence of 0.45% in this cohort. A literature survey yielded 31 previous GCT cases with a median age of 35 years, most of them were caused by occlusion of brain supplying arteries. Thrombotic occlusions of brain-supplying arteries secondary to cisplatin-based chemotherapy can arise in otherwise healthy young men with no risk factors for vascular disease. Care givers of GCT patients must be cognizant of such events upon counselling patients before chemotherapy, because this complication of treatment may foil the attempts of restoring health in a basically well curable disease.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of azacytidine for poly ADP-ribose polymerase inhibitor-induced myelodysplastic syndrome in ovarian cancer patient: a twofold triumph. 阿扎胞苷治疗卵巢癌患者聚adp核糖聚合酶抑制剂诱导的骨髓增生异常综合征的有效性：双重胜利。

IF 2.1 4区医学

Journal of Chemotherapy Pub Date : 2026-02-12 DOI: 10.1080/1120009X.2026.2628393

Stefano Fucina, Riccardo Vida, Arianna Dri, Rosanna Ciancia, Barbara Montante, Sabrina Orzetti, Mariagrazia Michieli, Michele Bartoletti, Antonino Ditto, Fabio Puglisi

引用次数: 0

Nab-paclitaxel for the treatment of cervical cancer: a systematic review of clinical safety and effectiveness. nab -紫杉醇治疗宫颈癌：临床安全性和有效性的系统评价。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2026-02-08 DOI: 10.1080/1120009X.2026.2625548

I Gusti Ngurah Agung Wiwekananda, Nik Ahmad Nizam Nik Malek, Agustina Tri Endharti, Happy Kurnia Permatasari

{"title":"Nab-paclitaxel for the treatment of cervical cancer: a systematic review of clinical safety and effectiveness.","authors":"I Gusti Ngurah Agung Wiwekananda, Nik Ahmad Nizam Nik Malek, Agustina Tri Endharti, Happy Kurnia Permatasari","doi":"10.1080/1120009X.2026.2625548","DOIUrl":"https://doi.org/10.1080/1120009X.2026.2625548","url":null,"abstract":"Cervical cancer remains a major global health burden, particularly in advanced and recurrent disease, where therapeutic options are limited. We conducted a systematic review of clinical studies evaluating nab-paclitaxel-based regimens in cervical cancer, following PRISMA 2020 guidelines. Literature published between 2015 and 2025 was identified across five databases, and risk of bias was assessed using the MINORS tool. Ten studies (five single-arm and five comparative; n = 417) were included. Nab-paclitaxel was administered in combination with chemotherapy, radiotherapy, or immunotherapy. Across single-arm studies, objective response rates ranged from 40% to 57%, with median progression-free survival of 4.5-9.1 months and overall survival of 8.9-16.6 months. Comparative studies suggested higher response rates with nab-paclitaxel-cisplatin regimens, particularly in neoadjuvant settings. Nab-paclitaxel-based combinations demonstrated generally manageable toxicity. However, interpretation is limited by study heterogeneity and the absence of randomized controlled trials.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2026-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146142411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mpox: there is still risk of global outbreak. 麻疹：仍有全球暴发的风险。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2026-02-01 Epub Date: 2025-03-13 DOI: 10.1080/1120009X.2025.2476830

Silvano Esposito, Chiara D'Amore, Flora Salzano, Pasquale Pagliano

引用次数: 0

Impact of SARS-CoV-2 infection on clinical characteristics, antibody levels, and immune responses in patients with malignant hematological tumors. SARS-CoV-2感染对恶性血液肿瘤患者临床特征、抗体水平和免疫反应的影响

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2026-02-01 Epub Date: 2025-02-13 DOI: 10.1080/1120009X.2025.2458377

Yan Li, Jing Zhang, Xiang Wang, Yan Wang, Ruili Wang, Yongzhen Chen, Changkai Chen, Yuyang Tian

{"title":"Impact of SARS-CoV-2 infection on clinical characteristics, antibody levels, and immune responses in patients with malignant hematological tumors.","authors":"Yan Li, Jing Zhang, Xiang Wang, Yan Wang, Ruili Wang, Yongzhen Chen, Changkai Chen, Yuyang Tian","doi":"10.1080/1120009X.2025.2458377","DOIUrl":"10.1080/1120009X.2025.2458377","url":null,"abstract":"This study evaluated SARS-CoV-2 infection impacts on clinical characteristics, antibody levels, and immune responses in 100 malignant hematological tumor patients. Laboratory assessments included hematological, biochemical, and inflammatory markers. Multivariable analysis identified age (OR = 1.56, p = 0.004), chemotherapy cycles (OR = 1.86, p < 0.001), comorbidities (OR = 3.15, p = 0.015), WBC count (OR = 1.79, p = 0.016), CRP (OR = 2.07, p = 0.007), ferritin (OR = 1.22, p = 0.035), IL-6 (OR = 1.59, p = 0.001), IgG (OR = 2.28, p = 0.037), CD8+ T cells (OR = 2.97, p = 0.005), and NK cells (OR = 0.80, p = 0.019) as COVID-19 risk factors. COVID-19 patients showed significantly higher hospitalization (30.77% vs 10.42%, p = 0.007), ICU admission (23.08% vs 6.25%, p = 0.019), and lower 1-year survival (59.62% vs 87.50%, p = 0.002) versus controls. SARS-CoV-2 infection induces hematological/immune alterations and worsens clinical outcomes in hematological malignancy patients, emphasizing their heightened vulnerability.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"54-65"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2026-02-01 Epub Date: 2025-01-07 DOI: 10.1080/1120009X.2024.2448644

Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur

{"title":"Immune-related adverse events not associated with survival in advanced or metastatic gastroesophageal cancers.","authors":"Omar Elghawy, Reema Patel, Abhishek Mullapudi, Martin Kurian, John Wang, Jessica Xu, Varinder Kaur","doi":"10.1080/1120009X.2024.2448644","DOIUrl":"10.1080/1120009X.2024.2448644","url":null,"abstract":"Immune checkpoint inhibitors (ICIs) have shown promise in the treatment of gastric and oesophageal cancers (GEC). Despite their promising efficacy, ICIs have been associated with unique side effects known as immune-related adverse events (IRAEs). Several studies have shown improved treatment responses in patients with IRAEs compared to those without IRAEs in various cancer types such as melanoma and non-small cell lung cancer. We performed a single-institution retrospective study to characterize IRAE incidence and association with treatment response in advanced GEC. We identified 70 patients with GEC who received ICI therapy; 20 (29%) developed an IRAE of any magnitude. The most common were colitis (35%) hypothyroidism (25%) and pneumonitis (20%). Median PFS and OS were not statistically different between IRAE and nonIRAE groups (10.4 vs. 11.3 months p = 0.6 and 11.0 vs. 12.9 months p = 1.0, respectively). This is in contrast to studies in other cancer types that have suggested association between IRAE and improved outcomes.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"47-53"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142948424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The gene-panel obtained by anti-PD-1 monotherapy for melanoma reveals prognostic markers and therapeutic targets. 通过抗pd -1单药治疗黑色素瘤获得的基因面板揭示了预后标志物和治疗靶点。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2026-02-01 Epub Date: 2025-02-13 DOI: 10.1080/1120009X.2025.2465013

Miaomiao Wang, Zhike Zhou, Yingying Wang, Lixin Wang

{"title":"The gene-panel obtained by anti-PD-1 monotherapy for melanoma reveals prognostic markers and therapeutic targets.","authors":"Miaomiao Wang, Zhike Zhou, Yingying Wang, Lixin Wang","doi":"10.1080/1120009X.2025.2465013","DOIUrl":"10.1080/1120009X.2025.2465013","url":null,"abstract":"To search for key drug resistance biomarkers and potential chemotherapeutic agents for combination therapy in melanoma patients. The common up-regulated differentially expressed genes were acquired from two cohort studies, GSE91061 and PRJEB23709. Univariate and multivariate Cox regression survival analyses were performed to screen for important prognostic biomarkers. A multi-gene panel including APP, ARHGAP42, GSTA4 and UCHL1, not only plays an important role in prognostic indicators, but also in predicting the probability of resistance to anti-PD-1 in patients with melanoma. Chemotherapy drug response models found five potential drugs, including all-trans retinoic acid, doxorubicin, etoposide, methotrexate and MG-132, were significantly associated with target genes in gene-panel. Molecular docking confirmed that potential drugs have good binding ability to target genes APP, GSTA4 and UCHL1, suggesting that the multi-gene panel is expected to provide assistance for drug resistance prediction and prognosis assessment and combination therapy in patients with anti-PD-1 resistant melanoma.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"66-79"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The efficacy and safety analysis of oral isavuconazole therapy of invasive pulmonary aspergillosis. 口服异维康唑治疗侵袭性肺曲霉病的疗效及安全性分析。

IF 1.8 4区医学

Journal of Chemotherapy Pub Date : 2026-02-01 Epub Date: 2025-06-28 DOI: 10.1080/1120009X.2025.2523659

Yanli Gu, Rong Zhang, Wei Ding, Bing Sun, Wei Chen, Zili Meng, Liang Chen

{"title":"The efficacy and safety analysis of oral isavuconazole therapy of invasive pulmonary aspergillosis.","authors":"Yanli Gu, Rong Zhang, Wei Ding, Bing Sun, Wei Chen, Zili Meng, Liang Chen","doi":"10.1080/1120009X.2025.2523659","DOIUrl":"10.1080/1120009X.2025.2523659","url":null,"abstract":"This retrospective study aimed to explore the efficacy and safety of oral isavuconazole in treating invasive pulmonary aspergillosis (IPA). Among 31 enrolled patients, 21 survived and 10 died by the 42-days follow-up. The mean hospitalization duration was 21.81 ± 8.03 days, with isavuconazole administered for a mean of 25.10 ± 12.87 days. Survivors received isavuconazole for significantly longer period than non-survivors (28.62 vs 17.70 days, P = 0.025). The time to initiation of isavuconazole was significantly shorter in survivors compared to non-survivors (7.86 vs 14.4 days, P = 0.013). Early initiation of treatment was significantly associated with a shorter hospital stay (16.33 vs 25.83 days, P < 0.001). No significant adverse effects were observed in laboratory parameters, and no patients discontinued treatment due to side effects. These findings suggest that early oral administration of isavuconazole may reduce mortality rates and shorten hospitalization duration in patients with IPA. The treatment demonstrated a favourable safety profile, with minimal adverse reactions.","PeriodicalId":15338,"journal":{"name":"Journal of Chemotherapy","volume":" ","pages":"25-31"},"PeriodicalIF":1.8,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144528188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0